GLP-1, GIP, and Glucagon Receptors: The Biology Behind Incretin Research Peptides
The incretin research peptides that dominate metabolic study today all act on the same small family of receptors. To understand why one compound targets a single receptor while another targets two or three, it helps to start with the biology of the receptors themselves rather than the peptides. Three receptors matter here: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Each is a class B G-protein-coupled receptor, and each has a distinct primary job. Once those jobs are clear, the mono, dual, and triple agonist design logic falls neatly into place.
| Receptor | Primary effect studied | Example peptide |
|---|---|---|
| GLP-1 receptor | Glucose-dependent insulin secretion and satiety signaling | Semaglutide |
| GIP receptor | Insulin secretion and adipose-tissue effects | Tirzepatide (with GLP-1) |
| Glucagon receptor | Hepatic glucose output and energy expenditure | Retatrutide (with GIP and GLP-1) |
One receptor family, one core signal
All three receptors belong to class B of the G-protein-coupled receptor superfamily, the group specialized for recognizing peptide hormones. They share a large extracellular domain that grips the peptide and a seven-transmembrane bundle that transmits the message inward. When activated, each couples primarily to the Gs protein and raises intracellular cyclic AMP (cAMP), which is the shared second messenger that carries the signal onward. Because the wiring is similar, a single engineered peptide can be shaped to fit more than one of these receptors at once. What differs is the physiology sitting downstream of each receptor, and that is where the three part ways.
The GLP-1 receptor
The GLP-1 receptor is the most studied of the three in a metabolic context. Its signature feature is glucose-dependent insulin secretion: it prompts the pancreatic beta cell to release insulin, but chiefly when blood glucose is elevated, which is why research on this pathway emphasizes a self-limiting action. Beyond the pancreas, GLP-1 receptor signaling in the brain is tied to satiety, and preclinical work has examined slowed gastric emptying as well. Semaglutide is the prototypical mono-agonist here, engineered to fit this single receptor with high potency and a long duration.
The GIP receptor
The GIP receptor, activated by glucose-dependent insulinotropic polypeptide, also supports insulin secretion from the beta cell, giving it an incretin role that parallels GLP-1. Its more distinctive research interest lies in adipose tissue, where GIP-receptor signaling has been investigated for effects on fat handling and nutrient storage. On its own the GIP arm has a more debated profile, but combined with GLP-1 activity it appears in the literature as a complementary rather than redundant signal.
The glucagon receptor
The glucagon receptor is the outlier of the group because glucagon is classically the counter-regulatory hormone to insulin. In the liver it drives hepatic glucose output, and this is why adding glucagon activity must be balanced carefully against the glucose-lowering aims of the other two arms. The reason it is of research interest at all is energy expenditure: glucagon-receptor signaling has been studied for its capacity to raise metabolic rate and mobilize stored fuel. In a well-designed multi-agonist, the appetite and insulin effects of the GLP-1 and GIP arms are intended to offset the glucose-raising tendency of the glucagon arm while retaining its energy-expenditure contribution.
Mono, dual, and triple agonist logic
With the receptors mapped, the peptides sort themselves out by how many of the three they engage. Semaglutide is a mono-agonist that targets the GLP-1 receptor alone. Tirzepatide is a dual agonist that targets both the GIP and GLP-1 receptors, pairing two incretin signals in one molecule. Retatrutide extends the concept to a triple agonist, adding glucagon-receptor activity on top of GIP and GLP-1 so that all three arms are engaged together. Each additional receptor is a deliberate design choice meant to recruit another slice of metabolic physiology rather than simply to increase potency at one site.
Reading the comparisons
Because these compounds differ by which receptors they touch, they are most instructive when set against one another. The pairing of a single-receptor and a triple-receptor design is covered in the semaglutide and retatrutide comparison, while the step from two receptors to three is examined in the tirzepatide and retatrutide comparison. Read together, they show how the same class B receptor biology supports a ladder of increasingly broad research peptides.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.